Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis

Context: Osteoporosis and osteopenia are associated with increased fracture incidence. Objective: The aim of this study was to determine the comparative effectiveness of different pharmacological agents in reducing the risk of fragility fractures. Data Sources: We searched multiple databases through 12/9/2011. Study Selection: Eligible studies were randomized controlled trials enrolling individuals at risk of developing fragility fractures and evaluating the efficacy of bisphosphonates, teriparatide, selective estrogen receptor modulators, denosumab, or calcium and vitamin D. Data Extraction: Reviewers working independently and in duplicate determined study eligibility and collected descriptive, methodological quality, and outcome data. Data Synthesis: This network meta-analysis included 116 trials (139,647 patients; median age, 64 yr; 86% females and 88% Caucasians; median follow-up, 24 months). Trials were at low to moderate risk of bias. Teriparatide had the

[1]  R. Eastell,et al.  Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  P. Sambrook,et al.  Antiresorptive therapies for osteoporosis: a clinical overview , 2012, Nature Reviews Endocrinology.

[3]  J. Reginster.  Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis , 2012, Drugs.

[4]  S. Silverman,et al.  The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures , 2012, Osteoporosis International.

[5]  Y. Kumagai,et al.  A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. , 2011, Bone.

[6]  R. Goeree,et al.  The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women , 2011, BMC musculoskeletal disorders.

[7]  Tianjing Li,et al.  Network meta-analysis-highly attractive but more methodological research is needed , 2011, BMC medicine.

[8]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[10]  C. Mok,et al.  Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial , 2010, Annals of the rheumatic diseases.

[11]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Genant,et al.  Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. , 2010, Bone.

[13]  E. Orwoll,et al.  Efficacy and safety of monthly ibandronate in men with low bone density. , 2010, Bone.

[14]  Jean-Pierre Devogelaer,et al.  Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. , 2009, Arthritis and rheumatism.

[15]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[16]  Stanley B. Cohen,et al.  Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial , 2009, The Journal of Rheumatology.

[17]  S. Boonen,et al.  Once‐Weekly Risedronate in Men With Osteoporosis: Results of a 2‐Year, Placebo‐Controlled, Double‐Blind, Multicenter Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  B. Clarke,et al.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial , 2009 .

[19]  Yoshiya Tanaka,et al.  Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy , 2008, The Journal of Rheumatology.

[20]  Daniel Solomon,et al.  Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture , 2008, Annals of Internal Medicine.

[21]  G. Guyatt,et al.  A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  R. Rajabian,et al.  The effect of bisphosphonate on prevention of glucocorticoid-induced osteoporosis , 2008 .

[23]  Martha Timmer,et al.  Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis , 2007, Annals of Internal Medicine.

[24]  P. Farahmand,et al.  Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study , 2008, Rheumatology International.

[25]  C. Mok,et al.  Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial , 2008, Osteoporosis International.

[26]  J. Nelson,et al.  Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer , 2007, Annals of Internal Medicine.

[27]  I. Olkin,et al.  The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.

[28]  K. Ando,et al.  Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. , 2006, Leprosy review.

[29]  J. Iwamoto,et al.  Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. , 2005, Archives of internal medicine.

[30]  J. Ioannidis.  Contradicted and initially stronger effects in highly cited clinical research. , 2005, JAMA.

[31]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[32]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[33]  A. Díez-Pérez,et al.  The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  Jacques P. Brown,et al.  Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. , 2001, Arthritis and rheumatism.

[35]  D. Reid,et al.  Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy , 2000, Calcified Tissue International.

[36]  E. Orwoll,et al.  Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.

[37]  M. Suarez‐Almazor,et al.  Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. , 2000, The Cochrane database of systematic reviews.

[38]  A. Avenell,et al.  Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. , 2000, The Cochrane database of systematic reviews.

[39]  D. Reid,et al.  Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  S. Wallach,et al.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.

[41]  Jacques P. Brown,et al.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. , 1998, The New England journal of medicine.

[42]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[43]  C. Cooper,et al.  Epidemiology of osteoporosis. , 2002, Best practice & research. Clinical rheumatology.

[44]  O. Norwood.  Density , 1993, International Society of Hair Restoration Surgery.

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.